U.S. FDA Warns Eisai’s Epilepsy Drug Could Risk Kidney, Bone Problems
This article was originally published in PharmAsia News
Executive Summary
Eisai's Zonegran (zonisamide) took a hit from U.S. FDA when the agency warned the epilepsy drug could increase the risk of kidney stones and bone disease. The drug, also sold as a generic, is approved for partial seizures in adult epilepsy patients in combination with other medications. FDA advised physicians Zonegran could cause metabolic acidosis, which leads to the other problems. The agency said it was requiring Eisai and generics makers to add the risk to a warning label, which would advise they be tested for the condition during treatment. (Click here for more - a subscription may be required
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.